Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Featured trial
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic pancreatic adenocarcinoma. Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), …

  • 0 views
  • 15 Oct, 2021
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic pancreatic adenocarcinoma. Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), …

  • 0 views
  • 15 Oct, 2021
  • 1 location
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer

This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with metastatic pancreatic adenocarcinoma. Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), …

  • 0 views
  • 15 Oct, 2021
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

drug test
azacitidine
lenalidomide
pancreatic cancer
cancer
  • 0 views
  • 16 Feb, 2024
  • 8 locations
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

solid neoplasm
solid tumour
treatment regimen
  • 0 views
  • 16 Feb, 2024
  • 1 location
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy for the treatment of patients with pancreatic cancer that has spread to nearby tissues or lymph nodes (locally advanced) or may be able to be …

leucovorin
neutrophil count
celiac disease
pancreatic cancer
fluorouracil
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of SGN-B6A in Advanced Solid Tumors

This trial will look at a drug called SGN-B6A to find out whether it is safe for people who have solid tumors. It will study SGN-B6A to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether …

lung cancer
breast cancer
bladder cancer
non-small cell lung cancer
cancer
  • 0 views
  • 05 Aug, 2020
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy

This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.

adenocarcinoma
cancer treatment
pancreatic cancer
cancer
pancreatic adenocarcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.

pancreatic cancer
cancer
pancreatic adenocarcinoma
diagnostic procedure
adenocarcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Analysis Of The Anxiety-Depressive Pattern Quality Of Life And Assessment Of Personality in Patients With Pancreatic Ductal Adenocarcinoma (PACT24)

The aim of this study is the evaluation of psychological aspects, such as anxiety-depressive patterns, quality of life, personality and other psychopathological syndromes of patients who receive a diagnosis of pancreatic cancer and who face chemotherapy treatment, radio-chemotherapy or surgery

ductal adenocarcinoma
pancreatic ductal adenocarcinoma
adenocarcinoma
pancreatic cancer
cancer
  • 0 views
  • 05 Aug, 2020